Showing results (181-190 of 447) with videos related to
Sort By:
Pageof 45
Respiratory Investigation|September 11, 2022
Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series studyYoshitaka Seki, Tatsuya Yoshida, Takashi Kohno, et al.Thoracic Cancer|March 27, 2019
Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancerNobumasa Tamura, Hidehito Horinouchi, Katsutoshi Sekine, et al.Japanese Journal of Clinical Oncology|March 28, 2019
Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II studySeiji Niho, Yukio Hosomi, Hiroaki Okamoto, et al.Journal of Cancer Research and Clinical Oncology|February 7, 2022
Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real worldSawako Kaku, Hidehito Horinouchi, Hirokazu Watanabe, et al.Journal of Gastroenterology|May 5, 2015
Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasionMasau Sekiguchi, Shigeki Sekine, Taku Sakamoto, et al.Japanese Journal of Clinical Oncology|June 1, 2007
Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecanYutaka Fujiwara, Ikuo Sekine, Yuichiro Ohe, et al.Cancer Chemotherapy and Pharmacology|February 2, 2018
Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancerTetsuhiko Taira, Kiyotaka Yoh, Seisuke Nagase, et al.Thoracic Cancer|October 27, 2020
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibodyShuji Murakami, Ryota Shibaki, Yuji Matsumoto, et al.Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohortIsamu Okamoto, Satoshi Morita, Naoki Tashiro, et al.Thoracic Cancer|January 20, 2021
HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIsSho Watanabe, Yasushi Goto, Hiroyuki Yasuda, et al.Pageof 45